NUVO
Navigation Links
NUVO in Medical News
Nuvo Announces 2009 second quarter financial results
... MISSISSAUGA, ON, Aug. 7 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...ation for the Study of Pain; and, - nuvo had $26.3 million in cash and cash equivalents at ...nsaid Plus. Subsequent to the quarter end, nuvo received additional proceeds of $5.7 milli...FDA extends review of Pennsaid(R) diclofenac sodium topical solution
...eading global provider of healthcare products, and nuvo Research Inc. (TSX:NRI), a Canadian drug developme... of November 4, 2009. During the review process, nuvo provided the FDA with supplemental information, wh... review process," stated Dan Chicoine, Chairman of nuvo Research. "Covidien is committed to the future s...... MISSISSAUGA, ON, June 16 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI) a Canadian drug developme...oidal anti-inflammatory drug ("NSAID") candidates. nuvo has been advised by the U.S. Food and Drug Adminis...he terms of the license and development agreement, nuvo will receive an up-front, non-refundable payment o...
Nuvo announces 2009 first quarter financial results
...MISSISSAUGA, ON, April 30 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...the PDUFA Date) by which the FDA intends to advise nuvo on Pennsaid's approvability - Recei...ntermann, President and Chief Executive Officer of nuvo Research. Financial Results: (thousa...Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
...MISSISSAUGA, ON, April 23 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...n-class product available in the United States." nuvo resubmitted its application for Pennsaid approval ...9. The FDA has indicated that it intends to advise nuvo of its decision regarding the approval of Pennsaid...Nuvo announces 2008 fourth quarter and year-end financial results
... MISSISSAUGA, ON, Feb. 27 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...ug User Fee Act by which the FDA intends to advise nuvo on Pennsaid's approvability - Annou...ntermann, President and Chief Executive Officer of nuvo Research. Financial Results: (thousands...Nuvo's High Throughput Experimentation Platform Selected as 2009 Edison Award Finalist
... MISSISSAUGA, ON, Feb. 24 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...edge research and development that we are doing at nuvo Research," said John M. Newsam, fqubed's President...n Awards, visit www.edisonawards.com . About nuvo Research Inc. ...FDA Accepts Nuvo's Resubmission For Pennsaid(R)
... -Provides nuvo with PDUFA date of August 5, 2009- MISSISSAUGA, ON, Feb. 19 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...r. The FDA has indicated that it intends to advise nuvo of its decision regarding Pennsaid approvability b...Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies
... MISSISSAUGA, ON, Jan. 28 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm... provide the FDA with the data it requires to give nuvo final, unconditional approval to market Pennsaid i.... Henrich Guntermann, President and CEO of Nuvo. nuvo is in the process of finalizing its resubmission f...Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company
... MISSISSAUGA, ON, Nov. 25 /PRNewswire-FirstCall/ - nuvo Research Inc. (TSX: NRI), a Canadian drug developm...entary experience with skin-applied products." nuvo acquired fqubed in 2005 to increase its ability to... products for delivery to or through the skin. The nuvo subsidiary has discovered molecular penetration en...NUVO in Medical Technology
... MISSISSAUGA, ON, Oct. 27 /PRNewswire-FirstCall/ - nuvo Research Inc.
(TSX: NRI), a Canadian drug developm...ollege of
Rheumatology Scientific Meeting provides nuvo with a forum to share our
compelling Pennsaid clin...served with Pennsaid than oral diclofenac.
About nuvo Research Inc.
...
... SAN CARLOS, Calif., April 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or ...
... -Webcast to Be Held at 4:30 p.m. ET today- SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that data from the Phase 2 program in catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of Non-functional and Occluded cath...
... SAN CARLOS, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced dosing of the first patient in a Phase 2 proof-of-concept trial of alfimeprase for the treatment of acute ischemic stroke. Nuvelo ...
... SAN CARLOS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it will hold a webcast and conference call to discuss results of the Phase 3 SONOMA-2 (Speedy Opening of Non-functional and Occ...
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
... - Phase 2 development to begin in late 2008 or in early 2009 - SAN CARLOS, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced positive results from the Phase 1b proof-of-concept trial of NU172, demonstrating that the direct thrombin inhibitor rapidly produce...Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
... - Phase 2 trial expected to begin in late 2008 or early 2009 - SAN CARLOS, Calif., June 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it has enrolled the first patient in a single-center, Phase 1b trial to determine the safety, tolerability and pharmacokinetics...Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
... 2 development to begin late in 2008 or in early 2009 - SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced positive results from the Phase 1 proof-of-concept trial (n=30) of NU172, demonstrating that the thrombin-inhibitor achieved rapid o...... SAN CARLOS, Calif., April 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or ...
... -Webcast to Be Held at 4:30 p.m. ET today- SAN CARLOS, Calif., March 17 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that data from the Phase 2 program in catheter occlusion (CO), known as SONOMA-3 (Speedy Opening of Non-functional and Occluded cath...
Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
... SAN CARLOS, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics ...... SAN CARLOS, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced dosing of the first patient in a Phase 2 proof-of-concept trial of alfimeprase for the treatment of acute ischemic stroke. Nuvelo ...
... SAN CARLOS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it will hold a webcast and conference call to discuss results of the Phase 3 SONOMA-2 (Speedy Opening of Non-functional and Occ...
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
...er, More Concentrated Dose of Alfimeprase - SAN CARLOS, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-...NUVO in Biological Technology
ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
...a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, and Nuvelo, Inc. (Nasdaq: nuvo ) today announced that Richard Brewer, ARCA's president and chief executive officer, will present at the 27th Annual JPMorgan Healthcare Conference on...... SAN CARLOS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that the stockholders of Nuvelo have approved the issuance of Nuvelo Common Stock pursuant to the merger agreement dated September 2...
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
... SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeuti...Nuvelo and ARCA biopharma Advance Toward Completion of Merger
... SAN CARLOS, Calif. and BROOMFIELD, Colo., Dec. 1 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) and ARCA biopharma, Inc., a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovas...ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
... JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 3:00 p.m. EDT in New York City. ARCA biopharma and Nuvelo, Inc. (Nasdaq: nuvo ) announced on September 25, 2008 that they have entered into a definitive merger agreement, expected to create a cardiovascular-focused, late-stage b...... at 8:30 a.m. EDT SAN CARLOS, Calif. and BROOMFIELD, Colo., Sept. 25 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) and ARCA biopharma, Inc., a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovas...
Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
... SAN CARLOS, Calif., July 29 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced that it has enrolled the first subject in a single-center, Phase 1 trial of recombinant, secreted protein, NU206, the company's lead...Nuvelo Reports Second Quarter 2008 Financial Results
... SAN CARLOS, Calif., July 23 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced second quarter 2008 financial results and accomplishments. For the second quarter ended June 30, 2008, Nuvelo reported a net loss ...Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...CVTX ) EDWARDS LIFESCIENCES CORP (NYSE: EW ) MEDICINES COMPANY (NASDAQ: MDCO ) MOMENTA PHARMACEUTICALS INC (NASDAQ: MNTA ) NUVELO INC (NASDAQ: nuvo ) PAR PHARMACEUTICAL COS INC. (NYSE: PRX ) SANGAMO BIOSCIENCES INC. (NASDAQ: SGMO ) SCIELE PHARMA INC. (NASDAQ: SCRX ) SPEEDEL HOLDING AG-REG (...Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
... SAN CARLOS, Calif., May 8 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: nuvo ) today announced first quarter 2008 financial results and provided an updated outlook for 2008. For the first quarter ended March 31, 2008, Nuvelo ...Other TagsUBMOther Contentsileumileumimprintingimprintingimprintingimmunoprecipitationimmunoprecipitationsilicositusitusitusitusitusitusitusituvitrovitrovitrovitrovitrovitrovitrovitrovitrovivovivovivovivovivovivovivovivovivocoefficientcoefficient
IntracanicularFlexPlugPrevailCINCHBioprosthesisBioprosthesesVenogramMicroscanABDv2UBMBioMicroscopeUltraScanKatzenChayet
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2[0] Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto[0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children[0] Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference[0] Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana[0] BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
(Date:12/2/2009)WEST LAFAYETTE, Ind. ╤ A Smoky Mountain forest,s woodland herb population has shown that climate may play a role in how forest understories recover from logging, according to Purdue University r
Breaking Biology News(10 mins):Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Study finds logging effects vary based on a forest's history, climate 2DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma 54723 1DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma 54723 2DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma 54723 3DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma 54723 4Nfocus Neuromedical Announces US Clearance of Unique Guiding Catheter with Uni body Internal Skeleton 54719 1Nfocus Neuromedical Announces US Clearance of Unique Guiding Catheter with Uni body Internal Skeleton 54719 2Aethlon Medical to Present at Todays Southern California Investor Conference 54714 1Aethlon Medical to Present at Todays Southern California Investor Conference 54714 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |